section name header

Pronunciation

kloh-PID-oh-grel

Classifications

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: platelet aggregation inhibitors

Indications

REMS


Action

  • Inhibits platelet aggregation by irreversibly inhibiting the binding of ATP to platelet receptors.
Therapeutic effects:
  • Reduction in risk of MI and stroke.

Pharmacokinetics

Absorption: Well absorbed following oral administration; rapidly metabolized to an active antiplatelet compound. Parent drug has no antiplatelet activity.

Distribution: Unknown.

Protein Binding: Clopidogrel: 98%; active metabolite: 94%.

Metabolism/Excretion: Rapidly and extensively converted by the liver via the CYP2C19 isoenzyme to its active metabolite, which is then eliminated 50% in urine and 45% in feces;2% of Whites, 4% of Blacks, and 14% of Asians have CYP2C19 genotype that results in reduced metabolism of clopidogrel (poor metabolizers) into its active metabolite (may result in antiplatelet effects).

Half-Life: 6 hr (active metabolite 30 min).

Time/Action Profile

(effects on platelet function)

ROUTEONSETPEAKDURATION
POwithin 24 hr3–7 days5 days



Following discontinuation.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Recent MI, Stroke, or Peripheral Arterial Disease

Acute Coronary Syndrome

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Plavix

Pill Image

clopidogrel_135-861.jpg